Tone mix
Week by week 52 weeks
Share of Genmab A/S ADS's 197 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 2, 2026 · tone -99EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)-109
- Week of Mar 9, 2026 · tone +99Narrow-Moat Genmab's Royalty Revenue Maintains Near-Term Growth as Pipeline Advancement Progresses+80
- Week of Jan 26, 2026 · tone -50EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)-77
- Week of Apr 20, 2026 · tone +100Genmab A/S (NASDAQ:GMAB) Upgraded by BNP Paribas Exane to "Strong-Buy" Rating+69
- Week of Apr 13, 2026 · tone +100Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln+68
- Week of Oct 20, 2025 · tone -25Genmab's Rina-S Achieves 50% Response Rate In Advanced Endometrial Cancer Trial-68
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Genmab A/S ADS in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 26 | +81 |
| Last 30 sessions | 44 | +66 |
| Last 90 sessions | 85 | +49 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
8 headlines, average tone +100: 8 positive, 0 neutral and 0 negative. Showing all 8.
- www.rttnews.com · 1 outletGenmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock UpPositive
- www.ibtimes.com.au · 1 outletGenmab Shares Jump 16% as Rally Builds on Cancer Drug Wins, JPMorgan Upgrade and Head and Neck Trial HopesPositive
- www.aol.com · 1 outletGenmab Stock Hits 52-Week High - Here's WhyPositive
- econotimes.com · 1 outletGenmab's Cancer Combination Meets Both Primary Endpoints in Phase 3 TrialPositive
- seekingalpha.com · 1 outletGenmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ)Positive
- www.rttnews.com · 1 outletGenmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial DataPositive
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck CancerPositive
- www.rttnews.com · 1 outletBiotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%Positive
Show the table · 8 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up | www.rttnews.com | 1 | Positive |
| Genmab Shares Jump 16% as Rally Builds on Cancer Drug Wins, JPMorgan Upgrade and Head and Neck Trial Hopes | www.ibtimes.com.au | 1 | Positive |
| Genmab Stock Hits 52-Week High - Here's Why | www.aol.com | 1 | Positive |
| Genmab's Cancer Combination Meets Both Primary Endpoints in Phase 3 Trial | econotimes.com | 1 | Positive |
| Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ) | seekingalpha.com | 1 | Positive |
| Genmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial Data | www.rttnews.com | 1 | Positive |
| Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer | www.finanznachrichten.de | 1 | Positive |
| Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
3 headlines, average tone +99: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.tickerreport.com · 1 outletJPMorgan Chase & Co. Upgrades Genmab A/S (NASDAQ:GMAB) to "Overweight"Positive
- www.themarketsdaily.com · 1 outletStock Analysts' Upgrades for October 26th (BTU, CNOB, DHR, GMAB, KALU, LKQ, RDY, ROP, SGE, SOTK)Positive
- www.rttnews.com · 1 outletGenmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck CancerPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| JPMorgan Chase & Co. Upgrades Genmab A/S (NASDAQ:GMAB) to "Overweight" | www.tickerreport.com | 1 | Positive |
| Stock Analysts' Upgrades for October 26th (BTU, CNOB, DHR, GMAB, KALU, LKQ, RDY, ROP, SGE, SOTK) | www.themarketsdaily.com | 1 | Positive |
| Genmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
15 headlines, average tone +67: 12 positive, 3 neutral and 0 negative. The 8 most widely carried stories are listed; the table holds all 15.
- www.rttnews.com · 1 outletGenmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal CancerPositive
- www.manilatimes.net · 1 outletGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerPositive
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerPositive
- www.manilatimes.net · 1 outletGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerPositive
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerPositive
- www.finanznachrichten.de · 1 outletGenmab A/S: Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerPositive
- www.finanznachrichten.de · 1 outletIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerPositive
- www.rttnews.com · 1 outletBiotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMABPositive
Show the table · 15 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal Cancer | www.rttnews.com | 1 | Positive |
| Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer | www.manilatimes.net | 1 | Positive |
| Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer | www.finanznachrichten.de | 1 | Positive |
| Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer | www.manilatimes.net | 1 | Positive |
| Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer | www.finanznachrichten.de | 1 | Positive |
| Genmab A/S: Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer | www.finanznachrichten.de | 1 | Positive |
| Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer | www.finanznachrichten.de | 1 | Positive |
| Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMAB | www.rttnews.com | 1 | Positive |
| Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer | www.rttnews.com | 1 | Positive |
| Genmab Reports Tumor Responses With Experimental Colorectal Cancer Combination | econotimes.com | 1 | Positive |
| Genmab and Incyte Plan Phase 1/2 Trial for KRAS G12D Colorectal Cancer | econotimes.com | 1 | Positive |
| Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ) | seekingalpha.com | 1 | Positive |
| Critical Contrast: Genmab A/S (NASDAQ:GMAB) vs. BioLineRx (NASDAQ:BLRX) | www.tickerreport.com | 1 | Neutral |
| Head to Head Contrast: Genmab A/S (NASDAQ:GMAB) and Novavax (NASDAQ:NVAX) | www.tickerreport.com | 1 | Neutral |
| Head-To-Head Contrast: Novavax (NASDAQ:NVAX) and Genmab A/S (NASDAQ:GMAB) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletGenmab A/S (OTCMKTS:GNMSF) Stock Short Interest Falls 44.4%Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab A/S (OTCMKTS:GNMSF) Stock Short Interest Falls 44.4% | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletGenmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over YearPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Genmab A/S ADS, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.